Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Humoral immune response after COVID-19 infection or BNT162b2 vaccine among older adults: evolution over time and protective thresholds

Maxence Meyer, Florentin Constancias, Claudia Worth, Anita Meyer, Marion Muller, Alexandre Boussuge, Georges Kaltenbach, Elise Schmitt, Saïd Chayer, Aurélie Velay, Thomas Vogel, Samira Fafi-Kremer, Patrick Karcher
doi: https://doi.org/10.1101/2021.11.19.21266252
Maxence Meyer
1Department of Geriatric, University Hospitals of Strasbourg, France
M.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: maxence.meyer@chru-strasbourg.fr
Florentin Constancias
2ETH Zürich, Department of Health Sciences and Technology, Zurich, Switzerland
Ph.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Claudia Worth
3Nuffield Department of Rheumatology, Orthopaedics and Musculosckeletal Sciences, University of Oxford
MB BChir.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anita Meyer
4COVID Vaccination Center, Offenburg, Germany
M.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marion Muller
1Department of Geriatric, University Hospitals of Strasbourg, France
M.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alexandre Boussuge
1Department of Geriatric, University Hospitals of Strasbourg, France
M.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Georges Kaltenbach
1Department of Geriatric, University Hospitals of Strasbourg, France
M.D., Ph.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elise Schmitt
1Department of Geriatric, University Hospitals of Strasbourg, France
M.D., Ph.D
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Saïd Chayer
5Department of Clinical Research and Innovations, University Hospitals of Strasbourg, France
PhD, HDR.,, Ph.D
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Aurélie Velay
6Laboratoire de Virologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
7INSERM, UMR_S1109, LabEx TRANSPLANTEX, Research Center for Immunology and Hematology, Faculty of Medicine, University Hospital Federation (FHU) OMICARE, Federation of Translational Medicine of Strasbourg (FMTS), University of Strasbourg, France
PharmD., Ph.D
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas Vogel
1Department of Geriatric, University Hospitals of Strasbourg, France
M.D., Ph.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Samira Fafi-Kremer
6Laboratoire de Virologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
7INSERM, UMR_S1109, LabEx TRANSPLANTEX, Research Center for Immunology and Hematology, Faculty of Medicine, University Hospital Federation (FHU) OMICARE, Federation of Translational Medicine of Strasbourg (FMTS), University of Strasbourg, France
PharmD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Patrick Karcher
1Department of Geriatric, University Hospitals of Strasbourg, France
M.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

INTRODUCTION The objectives of this study were to assess the dynamics of the SARS-CoV-2 anti-RBD IgG response over time among older people after COVID-19 infection or vaccination and its comparison with speculative levels of protection assumed by current data.

METHODS From November 2020 to October 2021, we included geriatric patients with serological test results for COVID-19.

We considered antibody titre thresholds thought to be high enough to protect against SARS-CoV-2 infection: 141 BAU/ml for protection/vaccine efficacy > 89.3%.

Three cohorts are presented. A vaccine group (n=34) that received two BNT162b2/Comirnaty injections 21 days apart, a group of natural COVID-19 infection (n=32) and a third group who contracted COVID-19 less than 15 days after the first BNT162b2/Comirnaty injection (n=17).

RESULTS 83 patients were included, the median age was 87 (81-91) years.

In the vaccine group at 1 month since the first vaccination, the median BAU/ml with IQR was 620 (217-1874) with 87% of patients above the threshold of 141 BAU/ml. Seven months after the first vaccination the BAU/ml was 30 (19-58) with 9.5% of patients above the threshold of 141 BAU/ml.

In the natural COVID-19 infection group, at 1 month since the date of first symptom onset, the median BAU/ml was 798 (325-1320) with 86.7% of patients above the threshold of 141 BAU/ml and fell to 88 (37-385) with 42.9% of patients above the threshold of 141 BAU/ml at 2 months. The natural infection group was vaccinated three months after the infection. Five months after the end of the vaccination cycle the BAU/ml was 2048 (471-4386) with 83.3% of patients above the threshold of 141 BAU/ml.

DISCUSSION On the humoral level, this supports the clinical results describing the decrease in vaccine protection over time.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This study did not receive any funding

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Ethics committee of the University Hospital of Strasbourg gave ethique approval for this work

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Impact statement We certify that this work is novel clinical research.

    This research adds to the literature descriptive data concerning the anti-RBD IgG immune response in elderly people, supposedly protective, in the context of both natural infection with COVID-19 as well as vaccination induced immunity. Notably, we present data for a prolonged follow up period of up to 300 days. We are not aware of a description of geriatric serology with BAU/ml, as currently recommended by WHO for universal comparison. We are also not aware of the comparison of the values of these serologies observed in geriatrics with theoretical protective thresholds.

  • Funding source No specific funding was received for this work.

Data Availability

All data produced in the present study are available upon reasonable request to the authors

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted November 19, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Humoral immune response after COVID-19 infection or BNT162b2 vaccine among older adults: evolution over time and protective thresholds
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Humoral immune response after COVID-19 infection or BNT162b2 vaccine among older adults: evolution over time and protective thresholds
Maxence Meyer, Florentin Constancias, Claudia Worth, Anita Meyer, Marion Muller, Alexandre Boussuge, Georges Kaltenbach, Elise Schmitt, Saïd Chayer, Aurélie Velay, Thomas Vogel, Samira Fafi-Kremer, Patrick Karcher
medRxiv 2021.11.19.21266252; doi: https://doi.org/10.1101/2021.11.19.21266252
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Humoral immune response after COVID-19 infection or BNT162b2 vaccine among older adults: evolution over time and protective thresholds
Maxence Meyer, Florentin Constancias, Claudia Worth, Anita Meyer, Marion Muller, Alexandre Boussuge, Georges Kaltenbach, Elise Schmitt, Saïd Chayer, Aurélie Velay, Thomas Vogel, Samira Fafi-Kremer, Patrick Karcher
medRxiv 2021.11.19.21266252; doi: https://doi.org/10.1101/2021.11.19.21266252

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (270)
  • Allergy and Immunology (552)
  • Anesthesia (135)
  • Cardiovascular Medicine (1757)
  • Dentistry and Oral Medicine (238)
  • Dermatology (173)
  • Emergency Medicine (312)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (659)
  • Epidemiology (10799)
  • Forensic Medicine (8)
  • Gastroenterology (590)
  • Genetic and Genomic Medicine (2949)
  • Geriatric Medicine (287)
  • Health Economics (534)
  • Health Informatics (1928)
  • Health Policy (836)
  • Health Systems and Quality Improvement (745)
  • Hematology (292)
  • HIV/AIDS (630)
  • Infectious Diseases (except HIV/AIDS) (12517)
  • Intensive Care and Critical Care Medicine (691)
  • Medical Education (299)
  • Medical Ethics (86)
  • Nephrology (324)
  • Neurology (2799)
  • Nursing (151)
  • Nutrition (433)
  • Obstetrics and Gynecology (559)
  • Occupational and Environmental Health (597)
  • Oncology (1466)
  • Ophthalmology (444)
  • Orthopedics (172)
  • Otolaryngology (257)
  • Pain Medicine (190)
  • Palliative Medicine (56)
  • Pathology (381)
  • Pediatrics (866)
  • Pharmacology and Therapeutics (366)
  • Primary Care Research (337)
  • Psychiatry and Clinical Psychology (2640)
  • Public and Global Health (5366)
  • Radiology and Imaging (1013)
  • Rehabilitation Medicine and Physical Therapy (595)
  • Respiratory Medicine (726)
  • Rheumatology (330)
  • Sexual and Reproductive Health (289)
  • Sports Medicine (279)
  • Surgery (327)
  • Toxicology (47)
  • Transplantation (150)
  • Urology (125)